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Abstract: Adenovirus infections of immunocompromised pediatric hematopoietic stem  
cell transplant patients can develop into serious and often deadly multi-organ disease. There 
are no drugs approved for adenovirus infections. Cidofovir (an analog of 2-deoxycytidine 
monophosphate) is used at times but it can be nephrotoxic and its efficacy has not been 
proven in clinical trials. Brincidofovir, a promising lipid-linked derivative of cidofovir, is in 
clinical trials. Ganciclovir, an analog of 2-deoxyguanosine, has been employed occasionally 
but with unknown efficacy in the clinic. In this study, we evaluated valganciclovir against 
disseminated adenovirus type 5 (Ad5) infection in our permissive immunosuppressed Syrian 
hamster model. We administered valganciclovir prophylactically, beginning 12 h pre-infection 
or therapeutically starting at Day 1, 2, 3, or 4 post-infection. Valganciclovir significantly 
increased survival, reduced viral replication in the liver, and mitigated the pathology associated 
with Ad5 infection. In cultured cells, valganciclovir inhibited Ad5 DNA replication and 
blocked the transition from early to late stage of infection. Valganciclovir directly inhibited 
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Ad5 DNA polymerase in vitro, which may explain, at least in part, its mechanism of action. 
Ganciclovir and valganciclovir are approved to treat infections by certain herpesviruses. Our 
results support the use of valganciclovir to treat disseminated adenovirus infections in 
immunosuppressed patients. 
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1. Introduction 
There are close to 70 types of human adenoviruses (Ads) described in the literature, named Ad1, Ad2, 
etc., that form seven species (A–G). Many Ad types are ubiquitous and quite benign, but under certain 
circumstances Ads can cause serious infections of the respiratory and gastrointestinal tracts, the eye, and 
other organs, and Ads can be very dangerous in immunocompromised patients (reviewed in [1,2]). There 
are no drugs approved specifically to treat Ad infections, i.e., no controlled clinical trials have been 
completed leading to approval of any anti-Ad drug. 
Cidofovir (CDV), an acyclic nucleoside phosphonate analog of 2-deoxycytidine monophosphate,  
is often used in the clinic for immunosuppressed pediatric allogeneic hematopoietic stem cell transplant 
patients with rising titers of Ad in the blood as determined by quantitative polymerase chain reaction 
(qPCR) [1,3–5]. Depending on the study, from 3% to 47% of such patients suffer disseminated Ad infections, 
and mortality can approach 100%. CDV (a monophosphate) is phosphorylated to the diphosphate form 
by cellular kinases; the diphosphate form is used as a substrate by the viral DNA polymerase, leading to 
incorporation of CDV and, eventually, to chain termination [6]. The specificity of CDV for many DNA 
viruses comes from the higher affinity of the viral enzymes for CDV-diphosphate. Unfortunately, CDV 
poses risk of kidney toxicity. 
A newly developed compound, brincidofovir (BCV) (formally named CMX001), is being evaluated 
in clinical trials [7] and case studies [8] with promising results. However, pivotal clinical trials must be 
completed before BCV can be approved. BCV is a lipid-linked derivative of CDV that is much more 
bioavailable than CDV and less nephrotoxic. BCV can diffuse easily through cellular membranes, after 
which the lipid moiety is removed by phospholipase C, leaving the CDV inside the cell. 
Recently, we have characterized CDV, BCV, and ribavirin regarding their anti-Ad efficacy in the 
immunosuppressed Syrian hamster model [9]. This animal model was developed in our laboratory [10,11]. 
In this model, Syrian hamsters are immunosuppressed by treatment with cyclophosphamide (CP), an 
agent that reduces white blood cell counts by ~7 fold in a few days [10,12-14]. While immunocompetent 
Syrian hamsters are permissive for species C human Ads [15,16], immunosuppression accentuates the 
pathology caused by the virus because the immune system cannot eliminate the infection [10]. Ad5 
administered intravenously (i.v.) is able to cause pathology and to replicate to high levels for extended 
periods in the liver and other organs. We found that CDV and BCV were very efficacious against human 
Ad5 in this animal model, while ribavirin was largely ineffective. 
In addition to CDV, BCV, and ribavirin, another small molecule inhibitor that has been used occasionally 
in the clinic against Ad, mostly in case studies, is ganciclovir (GCV) (reviewed in [1,3,5,17-20], an analog 
of 2-deoxyguanosine. GCV is approved to treat retinitis caused by human cytomegalovirus (HCMV) 
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(which can lead to blindness) and it is used for emergent HCMV infections in immunosuppressed 
transplant patients and AIDS patients. GCV must be phosphorylated to GCV-monophosphate by an 
HCMV-coded protein kinase (the UL97 protein kinase). Cellular kinases generate the GCV-diphosphate 
and GCV-triphosphate, the latter being a substrate for the viral DNA polymerase. The specificity for 
virus-infected cells comes from the initial phosphorylation of GCV by the viral kinase (cellular kinases 
phosphorylate GCV poorly if at all) and by more efficient use of GCV-triphosphate by the viral DNA 
polymerase than by cellular DNA polymerases. Unfortunately, there are very limited clinical data on the 
efficacy of GCV against Ad (see Discussion). One might think that GCV would not be active against Ad, 
considering, by analogy with HCMV, that GCV must be phosphorylated initially be a viral kinase, and 
that Ad is not known to encode such a kinase. Nevertheless, when we evaluated GCV in the hamster 
model, we found that its anti-Ad activity was similar to that of BCV [21]. 
Presently, valganciclovir (VGCV), a valyl-ester prodrug of GCV, is the most frequently used drug to 
prevent CMV infection after solid organ transplantation [22]. VGCV has much better oral availability than 
GCV, reaching 60% [23]. After uptake, the valine moiety is cleaved by intestinal and hepatic cellular 
esterases, yielding GCV, which, as mentioned, must be phosphorylated into its monophosphate form by a 
viral kinase and then into its triphosphate form by cellular kinases for its anti-herpesvirus activity. VGCV 
is approved for the treatment of HCMV retinitis associated with AIDS as well as disseminated infections 
in patients immunosuppressed during transplantation, especially of heart, kidney, and kidney-pancreas. 
We are unaware of any reports in the clinical literature or in animal studies on the use of VGCV to treat 
disseminated Ad infections. To determine if VGCV had anti-Ad activity, we tested if the drug could 
mitigate the effects of intravenous challenge with Ad5 in immunosuppressed hamsters. We report here that 
VGCV is very effective against Ad5-induced pathology and replication in the liver, even when the drug is 
given 4 days post-infection (p.i.) to hamsters challenged with the LD50 of Ad5, and 2 days p.i. when the 
hamsters are challenged with the LD90 of Ad5. At 2–4 days p.i., the titers of Ad5 in the liver are extremely 
high (~1010 infectious units per gram of liver) in untreated hamsters. Thus, it is especially promising that 
VGCV is efficacious at this stage of infection. Further, we provide initial evidence that VGCV (or GCV) 
may exert its anti-Ad5 effect by novel mechanisms—by directly inhibiting the Ad5 DNA polymerase 
and disturbing the intracellular nucleotide balance. 
2. Materials and Methods 
2.1. Materials 
A wild-type human Ad5 isolate, named Ad5 wt500, was used in all animal experiments. Ad5 wt500 
was derived by plaque purification from an Ad5 stock purchased from ATCC in our laboratory. The 
genome sequence of the isolate was verified to match the wild-type consensus sequence. The titer of the 
viruses was determined by plaque assay on human A549 cells. VGCV (batch 20120410) was purchased 
from 2A Pharmachem (Lisle, IL, USA), and dissolved in water at 3, 10, or 20 mg/mL for the animal 
doses of 30, 100, or 200 mg/kg. Syrian hamsters (Mesocricetus auratus) of approximately 100 g weight 
were purchased from Harlan Laboratories (Indianapolis, IN, USA). 
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2.2. Syrian Hamster Experiments 
All hamsters were immunosuppressed using CP. CP was administered intraperitoneally (i.p.) at a dose 
of 140 mg/kg, and then twice weekly at a dose of 100 mg/kg for the remainder of the experiment.  
For the studies in which the drug was dosed therapeutically, the animals were distributed into groups 
of 15 hamsters each, immunosuppressed with CP, and then injected i.v. with vehicle or 1.2 × 1010 PFU of 
Ad5 per 100 g body weight. We administered VGCV by oral gavage at 200 mg/kg, starting at 12 h before, 
or 1 day, 2 days, 3 days, or 4 days after Ad5 injection. In the Results and Figure Legends, these groups are 
referenced as −12 h, D +1, D +2, etc. After the initial administration of VGCV, it was administered twice 
daily for the remainder of the study. An Ad5-infected group that did not receive drug, and groups that 
received virus vehicle and drug vehicle only or virus vehicle plus drug (started at 12 h before challenge) 
were used as controls. 
For all animal experiments, the body weights and any signs of morbidity of the animals were recorded 
daily. On day 5 (for the experiment with female hamsters) or 7 (for the experiment with male hamsters), five 
hamsters of each group (designated at the start of the experiment) were sacrificed, and gross pathological 
observation was performed. Serum and liver samples were collected. Liver was fixed in 10% neutral-buffered 
formalin and tissues were subsequently routinely processed for paraffin embedding, sectioned, and stained 
with hematoxylin and eosin prior to microscopic evaluation. Virus burden in liver was determined by 
tissue culture infectious dose 50% (TCID50) assay. The serum was analyzed for liver transaminase levels. 
The remaining 10 hamsters were sacrificed at 16 (for the experiment with female hamsters) or 13 (for 
the experiment with male hamsters) days post challenge. Hamsters that became moribund before day 16 
were sacrificed as needed and processed as described above. Thus, there are two endpoints for these 
studies. One, collected from 10 animals, is survival and body weight gain/loss. The other, collected from 
5 animals for the day 5 time point, is virus burden in the liver and serum transaminase levels. 
The severity of microscopic pathology was scored on a scale ranging from 0 to 4 (no lesions: 0, minimal: 1, 
mild: 2, moderate: 3, marked: 4). Each group was assigned a composite severity score by averaging the 
individual scores. The distribution of the lesions was described as focal, multifocal, or diffuse.  
2.3. Determining the EC50 of VGCV 
A neutral red assay was used to quantify the inhibition of Ad cytopathic effect (CPE) by VGCV. Human 
A549 cells were plated in Dulbecco’s MEM containing 10% FBS at 8 × 103 cells per well  
(96-well plates) 1 day prior to infection. Cells were infected with various Ad serotypes (9 wells per drug 
concentration) or mock-infected (drug only controls). Virus concentrations were as follows: Ad5  
(1 PFU/cell), Ad6 (2 PFU/cell), or Ad4 (3 PFU/cell). At the end of the 1 h incubation, serially-diluted 
VGCV was added to the wells of the 96-well plate. Dilutions were set up as a 3-fold dilution series in 
serum-free DMEM. The final row of cells received medium with no drug added (the no drug control 
wells). Plates were incubated at 37 °C until the CPE reached ~50%–70% in the Ad-infected no drug 
treatment wells. At that time, 100 μL of neutral red (Sigma, St. Louis, MO, USA; diluted 1:10 in PBS) was 
added. After 1 h, plates were washed 3X with PBS. The neutral red was extracted by incubation with acidic 
alcohol solution (50% ethanol/1% acetic acid in water). The absorbance was read at 550 nm on a BioTek 
plate reader and data were analyzed using GraphPad Prism software. 
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To determine the 50% inhibitory concentration (IC50) for VGCV, A549 cells were set up as above one 
day prior to drug additions. VGCV was diluted in serial 1:3 dilutions (8 replicates per drug concentration) 
with no drug in the final row. Cell viability was assayed as above at 7 days post drug addition. 
2.4. Immunofluorescent Staining and Western Blot 
A549 cells, plated in 6-well plates on #1 glass cover glasses, were infected with representative Ad  
types, namely Ad5, Ad6 (species C), Ad7, Ad35 (species B), Ad4 (species E), Ad12 (species A), or Ad37 
(species D) at 5 to 10 PFU/cell in serum-free DMEM. At 90 min p.i., the medium was replaced with 
DMEM containing 5% FBS and 500 μM VGCV or no drug.  
For immunostaining, cells were fixed in 3.7% paraformaldehyde in PBS at 26 h p.i. and were 
permeabilized with cold methanol for 6 min and then rehydrated in PBS. Cells were stained with a rabbit 
anti-DBP antibody specific for the Ad-coded DNA Binding Protein (DBP) (gift of Maurice Green, Saint 
Louis University [24]) or a mouse monoclonal hexon-specific antibody reactive to all human Ads (2Hx-2, 
ATCC) [25]. Secondary antibodies were goat anti-rabbit IgG (Alexa Fluor 488 conjugate, Invitrogen 
Corp., Carlsbad, CA, USA) and goat anti-mouse IgG (Alexa Fluor 594 conjugate, Invitrogen Corp.). Cover 
glasses were mounted in mounting medium and images were taken with a Nikon DXM1200 digital camera 
mounted on a Nikon Optiphot microscope (Nikon, Melville, NY, USA) and using ACT-1 software (Nikon). 
All images were taken with the same exposure settings. 
For Western blot, cells were infected and treated as described above. At 24 h p.i, the cells were harvested 
and 20 μg of protein from each sample was electrophoresed on 15% SDS polyacrylamide gels and 
electroblotted onto an Immobilon PVDF membrane (Millipore, Bedford, MA, USA). The membrane was 
treated with TBST (50 mM Tris-HCl (pH 7.6), 150 Mm NaCl, 0.2% Tween 20) containing 5% dry milk 
overnight at 4 °C, and then probed with a rabbit antiserum generated against a TrpE fusion protein 
containing amino acids 54–227 of the Ad2 protein pVIII (pVIII is an Ad capsid protein that is synthesized 
exclusively at late stages of infection), or the same rabbit antiserum used in immunofluorescent staining 
for DBP. Primary antibodies were incubated with the membranes in TBST containing 5% dry milk at room 
temperature. The secondary antibody was goat anti-rabbit IgG-HRP conjugate (Cappel, Durham, NC, 
USA). The blots were visualized using LumiGlo® substrate (KPL, Gaithersburg, MD, USA). 
2.5. Quantitative PCR (qPCR) Assay for Quantification of Ad5 Genomic DNA 
We established a qPCR assay that allows direct quantitation of viral DNA copies in Ad5-infected A549 
cells. The extraction procedure effectively releases viral DNA from infected cells and a 1/10 dilution of 
the extracts was sufficient to eliminate the impact of any PCR inhibiting factors present in these extracts. 
A549 cells seeded in 24-well plates at 1 × 105 cells/well were either infected with Ad5 at 5 PFU/cell or 
mock-infected. After 90 min at 37 °C, the medium was aspirated and fresh DMEM containing serial dilutions 
(final concentrations ranging from 1 μM to 10 mM) of VGCV were added to the cells. Treatments were 
done in triplicate, and Ad5-infected cells with no-VGCV treatment as well as mock-infected cells receiving 
only VGCV were included as controls. At 24 h and 48 h p.i., the wells were washed twice with PBS, and 
the cells were lysed in 200 μL of lysis buffer (10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% SDS, 
0.5% NP40, 0.5% Tween-20, 0.5 mg/mL proteinase K) at 56 °C for 4–5 h. Proteinase K was then inactivated 
by boiling the reaction for 15 min. The samples were centrifuged at maximum speed in a microcentrifuge 
Viruses 2015, 7 1414 
 
 
for 10 min, and 5 μL of 10-fold diluted supernatant was used as template in a 25 μL qPCR reaction. 
TaqMan-based qPCR was used to quantify viral genome copies. The reaction conditions were described 
previously [16]. Amplification was performed in duplicate for each sample using an ABI model 7500 
genetic analyzer (Life Technologies, Grand Island, NY, USA). A standard curve generated using 102 to 
107 copies of purified Ad5 viral genomic DNA was employed to determine absolute viral genome copy 
number per cell. 
3. Results 
3.1. VGCV Protects Immunosuppressed Hamsters Challenged Intravenously with Ad5, Even When 
Administered Starting from Four Days after Ad5 Challenge 
In order to determine whether VGCV is active against Ad5 challenge when applied therapeutically 
(i.e., after challenge), we used the highest dose from the MTD experiment (200 mg/kg twice daily (b.i.d.) 
(Figure S1)). The dose of 200 mg/kg b.i.d. was found to be efficacious against i.v. Ad5 infection in CP-
treated Syrian hamsters when administered prophylactically (Figure S2). We started the treatment for 
different groups of Ad5-infected hamsters at 12 h before or 1, 2, 3, or 4 days after challenge and evaluated 
the efficacy of the drug. We performed two such experiments that were almost identical, with the exception 
that one of the studies did not have a day 4 start time group. Here we are showing the combined results 
of these two parallel experiments (Figure 1). 
 
Figure 1. Valganciclovir (VGCV) administered therapeutically increased survival and 
reduced weight loss after intravenous Ad5 challenge in immunosuppressed Syrian hamsters. 
(A) Survival. Ad5-Vehicle vs. Ad5 VGCV −12 h p = 0.0001, Ad5-Vehicle vs. Ad5 VGCV D 
+1 p = 0.0001, Ad5-Vehicle vs. Ad5 VGCV D +2 p = 0.0181, Ad5-Vehicle vs. Ad5 VGCV 
D +3 p = 0.0008, Ad5-Vehicle vs. Ad5 VGCV D +4 p = 0.0265 (Log rank); (B) Body weight 
changes. Each symbol represents values from individual animals. Every 3rd day shown for 
clarity. Ad5-Vehicle vs. Ad5-VGCV −12 h p < 0.0001, Ad5-Vehicle vs. Ad5-VGCV D +1 p 
< 0.0001, Ad5-Vehicle vs. Ad5-VGCV D +2 p < 0.0001, Ad5-Vehicle vs. Ad5-VGCV D +3 
p < 0.0001, Ad5-Vehicle vs. Ad5-VGCV D +4 not calculated (two-way ANOVA). 
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Ad5 challenge alone caused 55% mortality in this study; this was reduced to 0% in the −12 h and D +1 
groups, and to 16%, 5%, and 10% in the D +2, D +3, and D +4 groups, respectively (Figure 1A). All of 
these reductions were statistically significant (p < 0.0265). All the animals that were sacrificed ahead of 
schedule exhibited clinical signs associated with Ad5 infection (rapid weight loss, unthrifty look, 
dehydration, etc.) before becoming moribund.  
The Ad5-infected, vehicle-treated animals began losing weight starting from after virus challenge to 
ca. 6–9 days p.i.; the surviving hamsters then slowly started to gain weight but never reached the weight 
of the vehicle-challenged control animals (Figure 1B). VGCV administration resulted in significantly 
smaller (p < 0.0001) magnitude of weight loss for all groups that were treated with the drug, and by the 
conclusion of the study these animals had body weights similar to vehicle-challenged hamsters. No evidence 
of toxicity was observed with the drug-only control hamsters.  
Eight out of 10 Ad5-injected, vehicle-treated hamsters that were necropsied at 5 days p.i. had pale, 
yellow-mottled livers (data not shown). No animal was found with such pathology in the Ad5-VGCV  
−12 h and Ad5-VGCV D +1 groups. Eight out of 10, 5 out of 10, and one out of 5 hamsters exhibited 
liver pathology in the Ad5-VGCV D +2, Ad5-VGCV D +3, and Ad5-VGCV D +4 groups, respectively. 
All moribund hamsters sacrificed before schedule presented pathology characteristic of Ad5 infection. At 
16 days p.i., most animals had recovered from infection; 3 hamsters from the Ad5-infected, vehicle-treated 
group, one animal in each of the Ad5-VGCV D +1, Ad5-VGCV D +2, Ad5-VGCV D +4 groups, and 2 
animals in the Ad5-VGCV D +3 group had observable liver pathology.  
For the samples collected at 5 days post challenge, the histopathological analysis revealed moderate to 
marked multifocal hepatocellular necrosis with intranuclear inclusion bodies in the livers of Ad5-infected, 
vehicle-treated animals (composite score 3.4) (Table 1). Similar pathology was described for the animals 
that were sacrificed moribund.  
Table 1. Therapeutic administration of VGCV reduces the liver pathology induced by 
intravenous Ad5 challenge in immunosuppressed hamsters 
Group 
Animals 
affected 
Severity (average histopathology scores for hepatocellular 
necrosis (a representative lesion) are shown) 
Distribution 
Vehicle-Vehicle 0/5 N/A N/A 
Vehicle-VGCV 0/5 N/A N/A 
Ad5-Vehicle 5/5 3.4 Multifocal 
Ad5-VGCV −12 4/5 1.5 Multifocal 
Ad5-VGCV +1 5/5 1.8 Multifocal 
Ad5-VGCV +2 5/5 2.4 Multifocal 
Ad5-VGCV+3 4/5 1.75 Multifocal 
Hepatocellular necrosis with intranuclear inclusion bodies was observed in the livers of the  
VGCV-treated animals as well; however, the severity of the pathology was minimal to mild (composite 
score 1.5) in the −12 h group, minimal to mild (composite score 1.8) in the D +1 group, minimal to 
moderate (composite score 2.4) in the D +2 group, and minimal to mild (composite score 1.75) in the  
D +3 group (Table 1). 
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For the samples collected at 16 days post challenge, surviving animals showed signs of recovery, manifest 
by the absence of hepatocellular necrosis, and minimal to moderate subacute periportal inflammation, 
occasionally with Kuppfer cell nodules and mineralization. 
Serum was collected at necropsy and was analyzed for ALT and AST levels. As determined from the 
samples collected at 5 days p.i., VGCV treatment, even when started 1 day p.i., significantly reduced the 
magnitude of transaminase elevation caused by Ad5 replication (p = 0.0029 for ALT and p = 0.0007 for 
AST) (Figure 2A,B). At 15 days p.i., ALT and AST levels of all surviving animals were normal or only 
marginally elevated (data not shown).  
 
Figure 2. VGCV administered therapeutically significantly reduced the replication of Ad5 in 
the liver and consequent liver damage in immunosuppressed Syrian hamsters. Each symbol 
represents the value from an individual animal; the horizontal bar signifies the mean. Serum 
transaminase levels at 5 days p.i. (A) ALT: Ad5-Vehicle vs. Ad5-VGCV −12 h  
p = 0.0011, Ad5 vs. Ad5-VGCV D +1 p = 0.0029, Ad5 vs. Ad5-VGCV D +2 p = 0.2799, 
Ad5 vs. Ad5-VGCV D +3 p = 0.0355, Ad5 vs. Ad5-VGCV D +4 p = 0.4396; (B) AST: Ad5-
Vehicle vs. Ad5-VGCV −12 h p = 0.0011, Ad5 vs. Ad5-VGCV D +1 p = 0.0007, Ad5 vs. 
Ad5-VGCV D +2 p = 0.1903, Ad5 vs. Ad5-VGCV D +3 p = 0.0355, Ad5 vs. Ad5-VGCV D 
+4 p = 0.3710 (Mann-Whitney U test); (C) Virus burden in the liver in samples collected at 
day 5. Ad5-Vehicle vs. Ad5-VGCV −12 h p = 0.0021, Ad5 vs. Ad5-VGCV D +1 p = 0.0089, 
Ad5 vs. Ad5-VGCV D +2 p = 0.1230, Ad5 vs. Ad5-VGCV D +3 p = 0.1655, Ad5 vs. Ad5-
VGCV D +4 p = 0.8413 (Mann-Whitney U test); (D) Virus burden in the liver in samples 
collected at day 16. The empty symbols signify values from animals sacrificed moribund 
ahead of schedule. UD: undetectable, UQ: unquantifiable. 
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At 5 days p.i., all VGCV-treated groups, with the exception of the group for which treatment started  
4 days p.i., had lower virus burden in the liver (Figure 2C). The effect was most pronounced in the hamsters 
in the Ad5-VGCV −12 h (p = 0.0021) and Ad5-VGCV D +1 groups (p = 0.0089), for which an approximately 
100-fold decrease in Ad5 titers was observed. At 16 days p.i., the virus burden was undetectable for 
most VGCV-treated hamsters, while most surviving hamsters in the Ad5-injected, vehicle-treated group 
still had high virus burden in the liver (Figure 2D). 
3.2. VGCV Treatment Is also Effective in Male Syrian Hamsters 
In a follow-up experiment, we tested whether Ad5-challenged male hamsters responded differently to 
VGCV treatment than did females. In this study, we used the LD90 of Ad5 as challenge dose, which caused 
100% mortality with the Ad5-infected, vehicle-treated group (Figure 3A). Notably, all prophylactically 
treated hamsters survived, and there was a significant improvement (p = 0.0018) of survival with the 
groups that were treated 1 or 2 days p.i., in which 70% and 55% of the hamsters survived, respectively 
(Figure 3A). In the first 5 days of the study, all Ad5-infected hamsters lost weight rapidly; however, 
animals that were treated with VGCV 1 day before or 1 day after virus challenge started recovering after 
Day 6–7 (Figure 3B).  
 
Figure 3. Therapeutic administration of VGCV reduces mortality and morbidity of  
Ad5-infected male Syrian hamsters. (A) Survival. Ad5-Vehicle vs. Ad5-VGCV −12 h  
p < 0.0001, Ad5-Vehicle vs. Ad5-VGCV D +1 p = 0.0005, Ad5-Vehicle vs. Ad5-VGCV D +2 
p = 0.0018, Ad5-Vehicle vs. Ad5-VGCV D +3 p = 0.5264, Ad5-Vehicle vs. Ad5-VGCV D +4 
p = 0.0152 (Log Rank test); (B) Body weight changes. Each symbol represents the value from 
an individual animal; data from every second day are shown for clarity’s sake. Significance 
was not computed. 
For the purposes of gross pathology evaluation, animals sacrificed moribund before the Day 7 time 
point were grouped with animals that were scheduled to be sacrificed at that time. All 14 hamsters in the 
Ad5-Vehicle group had yellow, mottled, friable livers, as is characteristic for immunosuppressed hamsters 
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infected with high doses of Ad5. None of the 5 hamsters presented such pathology in the  
Ad5-VGCV −12 h group, and only 3 out of 7 in both the Ad5-VGCV D +1 and Ad5-VGCV D +2 groups 
had liver lesions. In these latter groups, the animals with Ad-specific pathology were all sacrificed 
moribund ahead of schedule. The Ad5-VGCV D +3 and Ad5-VGCV D +4 groups had 9 out of 11 and 5 
out of 9 hamsters with grossly abnormal livers, respectively. No significant findings were noted for the 
uninfected, vehicle- or VGCV-treated hamsters necropsied at 7 days post challenge.  
The animals that were sacrificed moribund at various time points after the Day 7 scheduled sacrifice 
presented pathology characteristic of systemic Ad5 infection. One observation stands out as heretofore not 
seen with female hamsters in our model: we noticed that several of these Ad-infected animals presented 
with gross evidence of intraperitoneal bleeding. 
At the conclusion of the study (Day 13), necrotic foci were observed in the liver of the hamsters in the 
Ad5-VGCV Day+2, +3, and +4 groups. The size and number of these lesions increased from occasional 
pinhead-sized foci in the Ad5-VGCV D +2 group to numerous 2–3 mm diameter foci in the Ad5-VGCV 
D +4 group. No gross pathology was observed with the hamsters in the Vehicle-Vehicle,  
Vehicle-VGCV, Ad5-VGCV −12 h, and Ad5-VGCV D +1 groups. 
For the samples collected at 7 days post challenge, the histopathological analysis revealed moderate to 
marked multifocal hepatocellular necrosis with intranuclear inclusion bodies in the livers of  
Ad5-infected, vehicle-treated animals (composite score 3.7) (Table 2). Similar pathology was present in 
the animals that were sacrificed moribund. 
Only 3 out of 5 and 4 out of 7 hamsters presented with hepatocellular necrosis with intranuclear 
inclusion bodies in the Ad5-VGCV -12 h and Ad5-VGCV D +1 groups, respectively, with a composite 
score of 0.6 (for both groups). Similar pathology was detected with the animals in the Ad5-VGCV D +2, 
Ad5-VGCV D +3, and Ad5-VGCV D +4 groups; however, the severity of the lesions was lower than in 
the case of Ad5-infected, vehicle-treated animals (Table 2). Surviving animals sacrificed at the conclusion 
of the study showed signs of recovery similar to those described for the experiment in which female 
hamsters were treated therapeutically with VGCV. 
Table 2. Therapeutic administration of VGCV reduces the liver pathology induced by 
intravenous Ad5 challenge in immunosuppressed hamsters (The table shows pathology for 
animals sacrificed between 4 and 9 days p.i.) 
Group 
Animals 
Affected 
Severity (average histopathology scores for hepatocellular 
necrosis (a representative lesion) are shown) 
Distribution 
Vehicle-Vehicle 0/5 N/A N/A 
Vehicle-VGCV 0/5 N/A N/A 
Ad5-Vehicle 15/15 3.7 Multifocal 
Ad5-VGCV −12 3/5 0.6 Focal/Multifocal 
Ad5-VGCV +1 4/7 0.6 Multifocal 
Ad5-VGCV +2 10/11 2.1 Multifocal 
Ad5-VGCV+3 13/14 2.9 Multifocal 
Ad5-VGCV+4 9/10 3.1 Multifocal 
Serum collected at necropsy was evaluated for ALT and AST (AST not shown) levels. For the purposes 
of evaluation, animals sacrificed moribund before the Day 7 time point will be grouped with animals that 
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were scheduled to be sacrificed at that time. Consistent with the liver pathology observed at necropsy, 
animals in the Ad5-Vehicle group had highly elevated ALT levels (Figure 4A). VGCV treatment 
significantly reduced this elevation, even when administration of the drug started two days after Ad5 
challenge (p = 0.0019). Notably, only hamsters that were sacrificed moribund ahead of schedule had 
highly elevated ALT levels in the Ad5-VGCV D +1 group (Figure 4A). 
Infectious virus load in the liver of Ad5-infected animals was determined by TCID50 assay. At 7 days 
p.i., animals treated with VGCV had significantly lower virus burden in the liver, irrespective of when the 
treatment started (Figure 4B). The effect was most pronounced in the hamsters in the Ad5-VGCV −12 h 
and Ad5-VGCV D +1 groups, for which over 100-fold decrease in Ad5 titers was observed. Similar to 
the serum ALT levels discussed above, only animals sacrificed moribund had grossly high virus burden 
in the Ad5-VGCV D +1 group. 
 
Figure 4. At 7 days post challenge, VGCV reduces the replication of Ad5 in the liver and 
mitigates Ad5-induced liver damage in male Syrian hamsters. Each symbol represents the 
value from an individual animal; the horizontal bar signifies the mean. Data from  
Ad5-infected animals sacrificed moribund ahead of schedule were included with the Day 7 
time point; these values are denoted by empty symbols. (A) Serum ALT levels.  
Ad5-Vehicle vs. Ad5-VGCV −12 h p = 0.0019, Ad5-Vehicle vs. Ad5-VGCV D +1  
p = 0.0100, Ad5-Vehicle vs. Ad5-VGCV D +2 p = 0.0019, Ad5-Vehicle vs. Ad5-VGCV D 
+3 p = 0.2418, Ad5-Vehicle vs. Ad5-VGCV D +4 p = 0.1887 (Mann-Whitney U-test);  
(B) Liver virus burden. Ad5-Vehicle vs. Ad5-VGCV -12 h p = 0.0016, Ad5-Vehicle vs. Ad5-
VGCV D +1 p = 0.0004, Ad5-Vehicle vs. Ad5-VGCV D +2 p = 0.0044, Ad5-Vehicle vs. Ad5-
VGCV D +3 p = 0.0489, Ad5-Vehicle vs. Ad5-VGCV D +4 p = 0.0033  
(Mann-Whitney U-test). 
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3.3. VGCV Inhibits the Growth of Human Ads in Vitro 
An in vitro viability assay was used to determine the ability of VGCV to inhibit Ad infection in the human 
A549 cell line. In addition to Ad5, infections were done with Ad6 (Species C) and Ad4 (Species E). The 
assay was done at a multiplicity of infection (MOI) that would ensure that the majority of cells were 
infected (ranging from 1–3 PFU/cell). Serial dilutions of VGCV were added 1 h after addition of the 
virus (VGCV was not replenished over the course of the assay). At 5–7 days p.i., EC50 values ranged from 
120.5 μM (Ad4) to 244.4 μM (Ad6) (Figure 5). Therefore, VGCV was able to inhibit multiple Ad serotypes 
in vitro. Inhibition of Ad7 and Ad35 (both Species B) also occurred with similar EC50 values (data not 
shown). A parallel plate was used to determine the IC50 for VGCV on A549 cells. At 7 days p.i., the IC50 
was calculated to be 11.74 mM. 
 
Figure 5. VGCV inhibits the growth of human Ads in vitro. A549 cells were infected with 
Ad5 (1 PFU/cell) (A), Ad6 (2 PFU/cell) (B), or Ad4 (3 PFU/cell) (C) and treated with serial 
dilutions of VGCVS. Cell viability was determined by neutral red assay at 5 d p.i. (Ad5, 
Ad6) or 7 d p.i. (Ad4). The IC50 for VGCV (D) was determined in parallel with neutral red 
addition at 7 d post drug addition. 
3.4. Treatment with VGCV Prevents Progression of Adenovirus Infection into the Late Stage 
Ad infection can be divided into early and late phases; the latter is characterized by the expression  
of Ad late (mostly virion, e.g., the hexon protein) proteins and requires the initiation of synthesis of Ad 
genomic DNA [26]. We performed immunoassays to find out if VGCV-treatment inhibited the production 
of Ad late proteins. Expression of the Ad hexon protein was dramatically decreased in VGCV-treated 
A549 cells infected with Ads belonging to five different species (Figure 6A). To demonstrate that VGCV 
had no effect on processes upstream of viral DNA replication, we stained the same cells for DBP as well. 
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DBP is an Ad protein that is synthesized initially prior to Ad DNA replication and whose synthesis continues 
well into the late stage of infection. In cells untreated with VGCV, DBP localized in a large number of 
replication centers; in some cases the entire nucleus stained positively for DBP (Figure 6A). This multitude 
of large replication centers, sometimes running together, which are seen at late stages of infection, are the 
site for Ad DNA replication and late gene transcription. In VGCV-treated cells, DBP was mostly confined 
to the original distinct replication centers associated with the input virus (this is an early DBP localization 
pattern; one infecting virion is thought to give rise to a single replication center) or showed uniform diffuse 
nuclear staining (a pattern seen in very early infection) (Figure 6A) [27,28], indicating that VGCV prevents 
the progression of the viral infection into the late phase.  
These results were supported by an immunoblot, in which we showed that VGCV treatment greatly 
reduced the expression of protein pVIII, another Ad capsid protein, in Ad-infected cultures (Figure 6B). 
Conversely, no changes were seen in the expression of DBP (except for the Ad12 infection) (Figure 6B). 
Taken together, these results indicate that the obstruction to Ad replication by VGCV takes place after 
early events of Ad infection (i.e., receptor binding, uptake, escape from the endosome, transport to the 
nucleus, and early gene expression), and before the expression of Ad late proteins such as hexon and pVIII. 
Further, they point to the broad spectrum of inhibition by VGCV, inasmuch as seven different types 
from five Ad species reacted similarly to the drug. 
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Figure 6. VGCV prevents adenoviral infection from advancing into the late phase. (A) 
Immunofluorescent staining for an early (DBP) and a late (hexon) Ad protein in  
VGCV-treated or untreated A549 cells, infected with species C (Ad5, 6), B (Ad7, 35), E 
(Ad4), A (Ad12), or D (Ad37) Ads. Uninfected cells did not stain with either antibody (data 
not shown); (B) Immunoblot staining for DBP and pVIII (another late Ad protein) in cells 
infected with the same types of Ads as in (A). 
3.5. VGCV Inhibits Ad5 DNA Replication 
Figure 7 shows the inhibition by VGCV of Ad5 DNA replication. The number of Ad5 DNA copies 
per cell at 24 h p.i. reached approximately 6000 copies/cell in untreated cells. VGCV treatment at  
1 μM did not show substantial inhibition of Ad5 DNA replication. In contrast, VGCV treatment at 100 
μM significantly reduced viral DNA replication to 70% of the level in the untreated control, and VGCV 
treatment at 1 mM knocked down viral DNA replication by 25-fold. The same fold inhibition was observed 
at 48 h p.i. even though the viral DNA copies increased by nearly 100-fold at 48 h p.i. compared to that 24 h 
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p.i. (data not shown). A dose response for VGCV is apparent in Figure 7. The calculated EC50 for VGCV 
to inhibit Ad5 DNA replication is 228 μM, which is in line with the EC50 in cell culture assays. Taken 
together, qPCR analysis of viral genomic DNA demonstrated potent anti-Ad5 activity of VGCV in vitro. 
A549 cells were infected with Ad5 at 5 PFU/cell. The infection was treated with different concentrations 
of VGCV for 24 h. The viral DNA was quantified by qPCR; it is presented as viral genome copy number 
per cell. The means of three biological replicates ± standard deviation are shown. Ad5 vs. Ad5 + VGCV 
1 μM p = 0.0649, Ad5 vs. Ad5 + VGCV 10 μM p < 0.01, Ad5 vs. Ad5 + VGCV 100 μM p < 0.01, Ad5 
vs. Ad5 + VGCV 1 mM p < 0.01, Ad5 vs. Ad5 + VGCV 10 mM p < 0.01 (Mann-Whitney U-test). 
 
Figure 7. VGCV inhibits adenoviral DNA replication in vitro. 
3.6. VGCV Inhibits Ad5 Replication by Mechanisms other than that Described for Herpesviruses 
We have shown elsewhere that ganciclovir (GCV), of which VGCV is a prodrug, is not phosphorylated 
in Ad5-infected cells, and that it is not incorporated into the viral genome [21]. Thus, VGCV (like GCV) 
probably inhibits Ad5 replication using alternative mechanisms. While the precise mechanism of this 
inhibition is unknown, here we present preliminary data suggesting two possible means of inhibition. 
We investigated whether unphosphorylated VGCV can directly inhibit the Ad5 DNA polymerase 
(Ad5 Pol) in vitro. As shown in Figure S3A, purified Ad5 Pol enzyme can utilize dNTPs in a primer 
extension assay in vitro and addition of increasing concentrations of VGCV to the reaction mixture reduced 
the extension efficacy of Ad5 Pol. This suggests that direct inhibition of the Ad DNA polymerase might 
be one of the mechanisms by which VGCV inhibits Ad5 replication. 
In searching for another mechanism of action for VGCV, we investigated whether a disturbance in 
nucleotide supply may be responsible for the inhibition of Ad replication. Optimal viral DNA synthesis 
requires an adequate amount of each nucleotide and appropriately balanced intracellular rNTP/dNTP 
pools. An imbalance of nucleotide pools could present a challenge for viral DNA and RNA polymerases 
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to select their proper substrate. To test whether alteration of nucleotide pools may contribute to the anti-Ad 
activity of VGCV, qPCR was employed to quantify viral DNA replication following supplementing 
Ad5-infected, VGCV-treated cells with various nucleotides. In the study, Ad5-infected A549 cells were 
treated with 500 μM VGCV, and then the same concentration of each individual nucleotide or nucleotides 
in combinations were added to the infection culture. Viral genomic DNA was quantified 24 h p.i. As shown 
in Figure S3B, VGCV treatment reduced viral DNA replication approximately 6-fold compared to the 
untreated control. Exogenous addition of purine nucleotides did not restore viral replication; in fact, dGTP 
further repressed viral DNA replication compared to GCV treatment alone (Figure S3B). Interestingly, 
supplementing VGCV-treated, Ad5-infected cells with pyrimidine nucleotides (dCTP + dTTP) increased 
Ad5 DNA replication two-fold compared to VGCV alone-treated infections (Figure S3B); however, no 
further enhancement beyond the two-fold increase in Ad5 DNA replication was achieved with addition 
of three deoxynucleotides (dATP, dCTP, and dTTP) or all four nucleotides (+dNTPs). These data 
demonstrate that supplementation with pyrimidine nucleotides partially reversed VGCV’s inhibition of 
Ad5 DNA replication. This suggests that an intracellular imbalance of purine/pyrimidine nucleotides 
caused by VGCV treatment may be one of the mechanisms by which VGCV inhibits Ad5 replication. 
4. Discussion 
We have employed the permissive immunosuppressed Syrian hamster model to study the ability of 
VGCV to inhibit Ad5 replication in the liver and Ad5-induced pathology. This model provides an excellent 
approximation of disseminated Ad5 infection in humans. We found that VGCV has strong activity against 
Ad5, significantly reducing Ad5-induced mortality, weight loss, replication in the liver, and pathology in 
the liver. 
We tested VGCV in a therapeutic setting, using a dose of 200 mg/kg/day, and administering the drug 
at 12 h prior to infection and Days +1, +2, +3, and +4 p.i. We found that VGCV significantly reduced 
Ad5 mortality, weight loss, and liver pathology at all time points of VGCV addition. At 5 days p.i., 
serum transaminase levels and the virus load in the liver were significantly reduced. Importantly, while 6 
out of the 9 surviving Ad5-infected, untreated hamsters had high virus burden in the liver at the conclusion 
of the study, the majority of VGCV-treated animals were virus-free by this time. The same dose of 
therapeutically administered VGCV significantly reduced mortality and morbidity of male hamsters 
infected with the LD90 of Ad5. With animals that started receiving the treatment at the −12 h, D +1, and 
D +2 time points, virus burden in the liver was 100-fold lower than in the Ad5-Vehicle group at 7 days 
p.i.. Considering that virus titers in the liver become extremely high at even 1 to 3 days p.i. and that there 
is on-going virus replication [10,16,29], it is quite remarkable that VGCV was efficacious when treatment 
was initiated at 1 or 2 days p.i., and even at 3 or 4 days p.i. in increasing survival. 
While further studies are needed to characterize the pharmacokinetics of VGCV in the hamster model, 
our results suggest that VGCV may be explored for possible use against disseminated Ad infections in 
immunocompromised patients. We have shown previously that GCV, the parental drug of VGCV, was 
active against Ad infection in hamsters, and there is anecdotal clinical evidence that GCV may be effective 
against Ad infection and pathogenesis in transplant patients [30-35]. In addition, treatment with 0.15% 
GCV ophthalmic gel improved the outcome of Ad conjunctivitis [36]. It seems reasonable that if GCV 
can be effective in the clinic, that VGCV should be effective as well. Previously, it was shown that GCV 
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and VGCV treatments are equally efficacious against CMV viraemia in immunocompromised patients 
[37]. Currently, clinicians favor the orally available VGCV over GCV that has to be administered 
intravenously. The 200 mg/kg b.i.d. dose that was shown to be efficacious against disseminated Ad5 
infection in hamsters is potentially clinically relevant, inasmuch as this corresponds to a calculated human 
equivalent dose of 27 mg/kg b.i.d., [38] and the recommended human dose of VGCV for the treatment of 
CMV retinitis is 15 mg/kg b.i.d. Additional studies are needed to determine the plasma concentration of the 
drug to establish the correlation between the dose used for the hamster studies and the human dose used 
in the clinic. 
We have shown that the EC50 of VGCV against various types of Ads in A549 cells is between  
120.5 μM (Ad4) and 244.4 μM (Ad6), while the IC50 is 11.7 mM. These values maybe overestimated, 
inasmuch as we do not know the rate of conversion of VGCV to GCV, the active compound, in this cell 
line. However, as the efficacy of esterases should equally influence the efficacy and toxicity of VGCV, 
the selectivity index (SI) value of 48 to 97 is probably valid. 
Regarding the mechanism of action of VGCV, we showed that the drug inhibits Ad DNA replication 
(Figure 7) and the transition from the early to late stage of infection (Figure 6A,B); the latter event requires 
the initiation of Ad DNA replication. The question arises as to whether VGCV functions against Ad5 in 
a manner analogous to its effect on herpesviruses. With herpesviruses, GCV (generated from VGCV) 
must first be phosphorylated by a viral-coded thymidine kinase (herpes simplex virus) or a protein kinase 
(HCMV), and then GCV-monophosphate is further phosphorylated to GCV-triphosphate by cellular 
kinases. The GCV-triphosphate is incorporated into viral DNA where it acts as a DNA chain terminator 
(see Introduction). In a separate study in which we examined the efficacy of GCV against Ad5 in the 
immunosuppressed Syrian hamster model, we found that [3H]GCV was not phosphorylated (or was 
barely phosphorylated) in Ad5-infected cultured A549 or HepG2 cells and it was not incorporated into 
Ad5 DNA [21]. We could not conduct such a study with VGCV since radiolabeled VGCV is not available. 
It is also notable that Ads are not known to encode a kinase. While we cannot exclude the possibility 
that VGCV gets phosphorylated in vivo, we do not think that the mechanism of action of VGCV against 
Ad5 involves phosphorylation of VGCV or GCV. Interestingly, preliminary data indicates that VGCV 
inhibits Ad5 DNA replication in a cell-free assay (Figure S3A). Thus, direct inhibition of the Ad DNA 
polymerase may be part of the mechanism by which VGCV is effective against Ad5 replication in cell 
culture and in Syrian hamsters. We have also shown that supplementing Ad5-infected cells with pyrimidine 
nucleotides partially reversed the inhibition of viral DNA synthesis by VGCV, suggesting that disturbing 
the intracellular nucleotide balance may be another mechanism by which VGCV inhibits the replication 
of Ad5. We want to stress the preliminary nature of these data; clearly, more work is needed to clarify 
the mechanism of action of VGCV in this system. 
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